Search Results
Your search for all items matches 35686 pages
Showing 1 - 50Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%
Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study...
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra), a DLL3-targeting bispecific T-cell engager, for adults with extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy....
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
Melanoma Cancer Cluster Found in Parts of Pennsylvania
Researchers have identified a melanoma cancer cluster in 15 counties in Pennsylvania near or containing cultivated croplands, according to findings published in JCO Clinical Cancer Informatics. The research highlights that sunlight and areas of higher herbicide use may contribute to these...
Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma
Patients with relapsed or refractory multiple myeloma who achieve a long-lasting disease remission from chimeric antigen receptor (CAR) T-cell therapy may differ from patients who relapse sooner based upon their immune system and how it responds to the infused CAR T cells, as well as how it...
Vorasidenib in IDH1/2-Mutant Low-Grade Glioma
As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with residual or recurrent IDH1-mutant or IDH2-mutant low-grade glioma. Initial reports at second...
Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel
Emese Zsiros, MD, PhD, of Roswell Park Comprehensive Cancer Center, reviews results from the randomized, double-blind, phase III ENGOT-ov65/KEYNOTE-B96 trial. According to the study investigators, “Pembrolizumab in combination with weekly paclitaxel with or without bevacizumab demonstrated...
Newly Diagnosed AL Amyloidosis: FDA Grants Traditional Approval to Regimen
On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. The FDA granted accelerated approval to the...
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant...
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Curative treatment following first-line immunotherapy is infrequently received, but when it was utilized, it significantly improved overall survival outcomes for patients with hepatocellular carcinoma, according to findings from a study published in Liver Cancer. The risk for death was improved by...
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo), a MEK inhibitor, for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In September 2025, the FDA approved selumetinib capsules and granules for...
New Study Explores Why Male Patients With AML May Have Worse Outcomes
New research has ruled out hormone signaling as the reason why men with acute myeloid leukemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine future research and could influence clinical trial design. The...
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
As reported in the The New England Journal of Medicine by Kunkler et al, the phase III SUPREMO trial showed no significant difference in 10-year overall survival in women with breast cancer receiving vs not receiving postmastectomy chest-wall irradiation. Study Details In the international trial...
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, in combination with lenalidomide and rituximab for the treatment of patients with relapsed or refractory follicular lymphoma. In addition, the FDA...
Dexrazoxane Use and Cardiovascular Health-Care Utilization in Children With Acute Myeloid Leukemia
In a U.S. cohort study reported as a research letter in JAMA Oncology, Zheng et al found that increasing use of dexrazoxane in newly diagnosed children with acute myeloid leukemia (AML) receiving front-line anthracycline treatment has been accompanied by a reduction in intensive care unit...
Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer
In a Canadian phase III trial (MAST) reported in the Journal of Clinical Oncology, Fleshner et al found that metformin did not improve progression-free survival vs placebo in men with low-risk prostate cancer undergoing active surveillance. Study Details In the multicenter double-blind trial, 408...
Quality Improvement Program Cuts Missed Radiation Appointments by 40%
A national quality improvement program led by the American College of Surgeons (ACS) found that transportation barriers and illness are among the top reasons patients with cancer miss critical radiation therapy appointments—and that providing hospitals and patients with structured support can...
Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma
In an interim analysis of a Chinese phase III trial (BL-B01D1-303) reported in The Lancet, Yang et al found that izalontamab brengitecan (iza-bren)—a bispecific antibody–drug conjugate targeting EGFR and HER3—significantly improved the objective response rate vs physician’s choice of chemotherapy...
Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma?
Based on the results of a multicenter retrospective cohort study published in JAMA Network Open, in patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma, a history of urinary stones was associated with significantly worse cancer-specific and disease-free survival....
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
Does Regular Opioid Use Increase Risks for Certain Cancers?
Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a large-scale study led by the International Agency for Research on Cancer (IARC) that was published in...
Could a Liquid Biopsy Lead to Earlier Diagnoses for Numerous Cancer Types?
Routine screening is limited to only a few cancer types. New research indicates that routine liquid biopsy testing (multicancer early detection testing) could substantially reduce late-stage cancer diagnoses, allowing patients to receive treatment at earlier stages of disease, when they are more...
More Patients With Cancer Are Using Crowdfunding to Pay for Care—and Coming up Short
Studies show that cancer is one of the leading diseases among all medical crowdfunding campaigns, with GoFundMe being the most popular platform for peer-to-peer medical donations. A new study by researchers at the American Cancer Society (ACS) has found that a growing number of cancer survivors are ...
MD Anderson Launches $2.5 Billion Philanthropic Campaign: Only Possible Here, The Campaign to End Cancer
The University of Texas MD Anderson Cancer Center has launched its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer. The campaign represents the largest fundraising effort in MD Anderson's 84-year history, bringing together philanthropic...
Pancreatic Cancer: Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Mild dilation of the main pancreatic duct without an apparent obstructing mass may be an independent risk factor for neoplastic progression to pancreatic cancer in high-risk individuals, according to findings from an analysis published in Gastro Hep Advances. “We are identifying pancreas duct...
FDA Approves New Interchangeable Biosimilar to Pertuzumab
The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta). This is the first approval of a biosimilar for pertuzumab. Pertuzumab-dpzb is a HER2/neu receptor antagonist indicated for the following: Use in combination...
Long-Term Continuous Nirogacestat in Adults With Desmoid Tumors
As reported in the Journal of Clinical Oncology by Ratan et al, long-term follow-up in the phase III DeFi trial has shown maintained benefits with prolonged nirogacestat treatment in patients with desmoid tumors. Study Details In the double-blind trial, 142 patients with progressing desmoid tumors...
Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium Lu-177–labeled PSMA–I&T (LuPSMA-I&T) and the bone-seeking alpha-emitter radium Ra-223 dichloride (Ra-223) was active in...
FDA Approves Ziftomenib for NPM1-Positive AML
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved ziftomenib (Komzifti), a menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options...
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
In a French phase II trial reported in The Lancet Oncology, Kim et al found that the combination of the PD-1 inhibitor ezabenlimab and induction chemotherapy with modified docetaxel, cisplatin, and fluorouracil (mDCF) and adaptive chemoradiotherapy was active in patients with treatment-naive stage...
Transfusion Access Central to Hospice Decision-Making Among Patients With Blood Cancers
Based on the results of a multicenter cross-sectional survey study published in JAMA Network Open by Raman et al, patients with blood cancer who were potentially hospice-eligible placed the greatest importance on transfusion access compared with routine hospice services. “The high value placed on...
Advanced Epithelial Ovarian Cancer: First-Line PARP Inhibitor Maintenance Therapy and Survival
A systematic review and meta-analysis published in JAMA Network Open found first-line PARP inhibitor maintenance after platinum-based chemotherapy was linked to improved progression-free survival across multiple patient populations with advanced-stage epithelial ovarian cancer. However, according...
Exercise Training Improves Strength and Quality of Life for Patients With Metastatic Breast Cancer
Supervised aerobic and resistance exercise can improve the physical performance and strength of patients living with metastatic breast cancer, according to new data from the PREFERABLE-EFFECT study that was presented by Anne May, PhD, during the Advanced Breast Cancer Eighth International Consensus ...
Supportive Care: Most Clinic Staff Prefer People-Focused vs Digital Solutions
Most cancer clinic staff prefer a team-based approach to supportive cancer care services over a technology-based approach, according to the results of a mixed-methods study of supportive care perceptions that was published in JNCCN—Journal of the National Comprehensive Cancer Network. The study...
Longtime FDA Innovator Appointed as Director of CDER
The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced that Richard Pazdur, MD, has been appointed Director of the Center for Drug Evaluation and Research (CDER). Dr. Pazdur is a 26-year veteran of the FDA and the Founding Director of its...
Addition of Eryaspase to Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
In a phase III trial (TRYBECA-1) reported in the Journal of Clinical Oncology, Hammel et al found that the addition of eryaspase (suspension of erythrocytes encapsulating L-asparaginase) to chemotherapy did not significantly improve outcomes in second-line treatment of patients with advanced...
T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Tolaney et al, interim analysis of the phase III DESTINY-Breast09 trial has shown significantly improved progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) plus pertuzumab vs a taxane (paclitaxel or docetaxel), trastuzumab,...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
Global Report Highlights Decade of Uneven Progress in Advanced Breast Cancer Care
ABC Global Alliance's landmark Advanced Breast Cancer Global Decade Report 2015–2025 was recently released and published in The Breast. The report highlights significant advancements made over the past decade that have transformed care for patients with advanced breast cancer, but also reveals gaps ...
Model for Predicting Risk of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
In a study reported in JAMA Oncology, Barac et al developed a risk prediction model for heart failure or cardiomyopathy (HF/CM) after breast cancer treatment. Study Details The aim of the study was to construct a model predicting the 10-year risk of developing HF/CM in women receiving systemic...
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older. As the incarcerated population ages, cancer has become one of the greatest threats to their health. And despite the growing prevalence, cancer...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Making Clinical Trials More Accessible: New Report Highlights Barriers and Solutions
Clinical trials remain out of reach for many Americans, with only 7% of patients with cancer participating in clinical trials, according to a new report from the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series. Experts agree that access to trials is a key...
